Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.54 |
| ▸ | PKM | P14618 | 2/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | DPP4 | P27487 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | TNF | P01375 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7975763 | 0.79 | ALDH1A1 (0.56) | ALDH1A1PKMHTTSMN1; SMN2CYP1A2 | |
| SCHEMBL2070257 | 0.75 | PKM (0.78) | ALDH1A1PKMHTTSMN1; SMN2CYP1A2 | |
| SCHEMBL10510922 | 0.75 | PKM (0.49) | ALDH1A1PKMHTTSMN1; SMN2KMT2A | |
| SCHEMBL7513265 | 0.73 | KDM4E (0.59) | ALDH1A1PKMSMN1; SMN2CYP2C9CYP2C19 | |
| SCHEMBL1197137 | 0.73 | ALDH1A1 (0.45) | ALDH1A1SMN1; SMN2CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL9687963 | 0.72 | PKM (0.47) | ALDH1A1PKMHTTSMN1; SMN2KMT2A | |
| SCHEMBL27545740 | 0.72 | PKM (0.52) | ALDH1A1PKMHTTSMN1; SMN2KDM4E | |
| SCHEMBL2568595 | 0.72 | ALDH1A1 (0.44) | ALDH1A1SMN1; SMN2CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL3473414 | 0.72 | PKM (0.59) | ALDH1A1PKMHTTSMN1; SMN2KMT2A | |
| SCHEMBL7585822 | 0.71 | ALDH1A1 (0.53) | ALDH1A1PKMHTTSMN1; SMN2CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1400510-B1 | CYCLIC DIAMINE COMPOUNDS HAVING FUSED-RING GROUPS | KOWA CO (JP) | 2010-08-18 | — | — | EP | disclosed |
| US-7135473-B2 | Cyclic diamine compound with condensed-ring groups | KOWA CO., LTD. (JP) | 2006-11-14 | — | — | US | disclosed |
| US-20040058913-A1 | Cyclic diamine compound with condensed-ring groups | KOWA CO., LTD. (JP) | 2004-03-25 | — | — | US | disclosed |
| EP-1400510-A1 | CYCLIC DIAMINE COMPOUNDS HAVING FUSED-RING GROUPS | Kowa Co., Ltd. (JP) | 2004-03-24 | — | — | EP | disclosed |
| US-6632810-B2 | Such as N,N'-bis((5,6,7-trimethoxynaphthalen-2-yl)methyl) piperazine, which has inhibitory effects on cell adhesion, for treatment of allergy, asthma, rheumatism, arteriosclerosis, and inflammation | KOWA CO., LTD. (JP) | 2003-10-14 | — | — | US | disclosed |
| US-20030060461-A1 | Cyclic diamine compound with condensed-ring groups | KOWA CO., LTD. (JP) | 2003-03-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040058913-A1 | Cyclic diamine compound with condensed-ring groups | HRH4, HRH3, HRH1 | ALDH1A1 468/4885PKM 4613/4885HTT 3478/4885 |
| US-20030060461-A1 | Cyclic diamine compound with condensed-ring groups | HRH4, HRH3, HRH1 | ALDH1A1 468/4885PKM 4613/4885HTT 3478/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.